219 related articles for article (PubMed ID: 11859670)
1. [Brain metastasis of prostatic cancer: regression under hormonal treatment].
Ameur A; Touiti D; el Mostarchid B; el Alami M; Jira H; Abbar M
Prog Urol; 2001 Dec; 11(6):1298-301. PubMed ID: 11859670
[TBL] [Abstract][Full Text] [Related]
2. [A case of brain metastasis associated with prostate cancer].
Soga N; Sugimura Y
Hinyokika Kiyo; 2004 Jan; 50(1):37-40. PubMed ID: 15032014
[TBL] [Abstract][Full Text] [Related]
3. Total androgen blockade in the treatment of hormone-resistant metastasized prostate carcinoma. A literature review.
Oosterlinck W; Mast P
Acta Urol Belg; 1994 Apr; 62(1):67-71. PubMed ID: 8197932
[TBL] [Abstract][Full Text] [Related]
4. Improved prostate cancer treatment.
Health News; 2002 Sep; 8(9):8. PubMed ID: 12229905
[No Abstract] [Full Text] [Related]
5. [Cyproterone acetate (Androcur-depo) in the treatment of inoperable prostatic cancer].
Stepanov VN; Goriunov VG; Chechenin MG; Sivkov AV; Gubdurakhmanov II
Urol Nefrol (Mosk); 1995; (6):33-6. PubMed ID: 8686122
[TBL] [Abstract][Full Text] [Related]
6. [Cyproterone acetate and cancer of the prostate. Experience in 46 cases].
Tauveron I; Hermabessière J
Therapie; 1988 May; 43(3):175-7. PubMed ID: 2971277
[No Abstract] [Full Text] [Related]
7. [Chronic myeloid leukemia and carcinoma of the prostate].
Papineschi F; Bonini R; Pistolisi D; Spremolla G
Sangre (Barc); 1989 Oct; 34(5):383. PubMed ID: 2533407
[No Abstract] [Full Text] [Related]
8. [Hypercalcemia: a finding indicative of a prostatic adenocarcinoma].
Llarena Ibarguren R; Acha Pérez M; Zabala Egurrola JA; Pertusa Peña C
Actas Urol Esp; 1989; 13(5):409-10. PubMed ID: 2531967
[TBL] [Abstract][Full Text] [Related]
9. [Neuroendocrine differentiation in adenocarcinoma of the prostate during hormonal treatment: a case report].
Matsumoto Y; Mibu H; Kagebayashi Y
Hinyokika Kiyo; 2004 Nov; 50(11):813-5. PubMed ID: 15628545
[TBL] [Abstract][Full Text] [Related]
10. Proptosis--an uncommon presentation of orbital metastases secondary to prostate cancer.
Vissamsetti B; McArdle PA; Adams CJ; Hotiana Z; Morton AL; Alexander RJ
Urol Int; 2007; 79(4):374-5; discussion 375. PubMed ID: 18025861
[TBL] [Abstract][Full Text] [Related]
11. Metastatic prostate cancer treated by flutamide versus cyproterone acetate. Final analysis of the "European Organization for Research and Treatment of Cancer" (EORTC) Protocol 30892.
Schröder FH; Whelan P; de Reijke TM; Kurth KH; Pavone-Macaluso M; Mattelaer J; van Velthoven RF; Debois M; Collette L;
Eur Urol; 2004 Apr; 45(4):457-64. PubMed ID: 15041109
[TBL] [Abstract][Full Text] [Related]
12. [Neuroendocrine differentiation and metastasized to brain stem, intraorbit and base of tongue in prostate cancer during hormonal treatment: a case report].
Sugi M; Yanishi M; Shimada O; Kawakita S; Murota T; Shikata N
Hinyokika Kiyo; 2008 May; 54(5):373-6. PubMed ID: 18546865
[TBL] [Abstract][Full Text] [Related]
13. Intracranial treatment for solitary prostatic adenocarcinoma brain metastasis is curative.
Sweets T; Bracken RB; Geisler EJ; Warnick R
Urology; 2009 Mar; 73(3):681.e7-9. PubMed ID: 18502485
[TBL] [Abstract][Full Text] [Related]
14. [Giant prostate carcinoma treated effectively with endocrine therapy: case report].
Masue N; Hasegawa Y
Hinyokika Kiyo; 2007 Feb; 53(2):133-5. PubMed ID: 17352166
[TBL] [Abstract][Full Text] [Related]
15. Locally advanced prostate cancer--biochemical results from a prospective phase II study of intermittent androgen suppression for men with evidence of prostate-specific antigen recurrence after radiotherapy.
Bruchovsky N; Klotz L; Crook J; Goldenberg SL
Cancer; 2007 Mar; 109(5):858-67. PubMed ID: 17265527
[TBL] [Abstract][Full Text] [Related]
16. Pulmonary metastases, an occult prostatic adenocarcinoma and delayed administration of antiandrogens.
Harris SJ; Cowley N
Clin Oncol (R Coll Radiol); 1996; 8(2):118-9. PubMed ID: 8859611
[TBL] [Abstract][Full Text] [Related]
17. Comparison of proliferating cell nuclear antigen immunostaining in lymph node metastases and primary prostate adenocarcinoma after neoadjuvant androgen deprivation therapy.
Minardi D; Galosi AB; Giannulis I; Montironi R; Polito M; Muzzonigro G
Scand J Urol Nephrol; 2004; 38(1):19-25. PubMed ID: 15204422
[TBL] [Abstract][Full Text] [Related]
18. Final results of the Canadian prospective phase II trial of intermittent androgen suppression for men in biochemical recurrence after radiotherapy for locally advanced prostate cancer: clinical parameters.
Bruchovsky N; Klotz L; Crook J; Malone S; Ludgate C; Morris WJ; Gleave ME; Goldenberg SL
Cancer; 2006 Jul; 107(2):389-95. PubMed ID: 16783817
[TBL] [Abstract][Full Text] [Related]
19. [Case of progressive prostatic carcinoma in a patient with acquired hypogonadism].
Inahara M; Yamazaki K; Ishida Y; Kojima S
Hinyokika Kiyo; 2010 Apr; 56(4):241-4. PubMed ID: 20448451
[TBL] [Abstract][Full Text] [Related]
20. [Drug treatment of prostatic carcinoma].
Kool JC
Ned Tijdschr Geneeskd; 1997 Nov; 141(45):2202-3. PubMed ID: 9550808
[No Abstract] [Full Text] [Related]
[Next] [New Search]
